A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...
There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.
News-Medical.Net on MSN
Semaglutide helps older adults lose weight without immediate bone loss
Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...
The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic ...
The MarketWatch News Department was not involved in the creation of this content. -- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback